Mass Tort brief
Mass Tort Briefing: High Court Disputes and Global Liabilities
London litigation battles over BHP and AI device liability unfold alongside major US mass tort developments.
Mass Tort
An internal law firm feud over Britain's £36B BHP dam lawsuit risks delaying damages hearings for 420,000 Brazilian claimants — threatening the momentum of England's largest mass tort.
BackgroundThe London High Court lawsuit against mining giant BHP over the 2015 Fundão dam collapse represents the largest mass tort action in English legal history. Pogust Goodhead secured a landmark liability ruling against BHP in late 2025, establishing British jurisdiction over the disaster.
- Ousted former Pogust Goodhead CEO Thomas Goodhead is actively backing the rival law firm takeover effort, intensifying internal friction among claimant representatives.
- Pogust Goodhead requested urgent High Court injunctions to void the termination notice, arguing the client committee lacked authority to strip them of primary case control.
- The leadership dispute threatens to disrupt critical legal preparations, risking multi-month delays for upcoming High Court damages assessment hearings scheduled later this year.
Mass Tort
The $40M Bard PowerPort bellwether verdict escalates pressure on parent company Becton Dickinson to negotiate a global settlement across thousands of catheter claims.
BackgroundMultidistrict litigation consolidates thousands of claims alleging C.R. Bard's implantable vascular ports fracture inside patients during routine medical treatments. Bellwether trials test jury reactions to evidence, establishing financial benchmarks for eventual global settlement negotiations across medical device sectors.
- The $40 million award follows evidence showing barium sulfate degradation compromised catheter structural integrity, causing internal fragmentation inside patients' cardiovascular systems.
- Parent company Becton Dickinson faces mounting settlement pressure across thousands of pending device lawsuits as plaintiffs win consecutive multi-million-dollar jury verdicts.
- Plaintiffs suffered severe internal complications including catheter fragment migration, blood infections, and permanent vascular damage requiring emergency surgery.
Mass Tort
GSK's final lien resolution under its $2.2B Zantac deal clears legacy litigation overhang — freeing the UK drugmaker to deploy capital toward pharma development.
BackgroundGSK faced massive US liability exposure over allegations that heartburn drug Zantac degraded into carcinogenic NDMA over time. The $2.2 billion master settlement resolved roughly 93% of pending US state and federal cases, removing severe litigation overhang from the UK pharmaceutical giant.
- Special masters are verifying federal and state medical reimbursement claims to ensure healthcare providers are repaid before claimants receive individual cash distributions.
- Completing the final lien releases eliminates legacy litigation uncertainty that depressed GSK equity valuations and dragged down broader London pharma sentiment for years.
- A small fraction of unresolved state court claims remain active in Delaware, though analysts expect remaining suits to pose minimal systemic financial risk.
Mass Tort
Evidentiary rulings in the Ozempic MDL will decide whether 4,000 stomach paralysis claims reach juries or get dismissed — setting benchmarks for global GLP-1 litigation.
BackgroundGLP-1 receptor agonist medications like Ozempic, Wegovy, and Mounjaro have grown into multi-billion-dollar treatments for diabetes and weight loss across global markets including the UK. Plaintiffs contend manufacturers failed to adequately warn users regarding severe gastrointestinal side effects including intestinal blockages.
- The federal court is evaluating general causation testimony linking GLP-1 drugs to severe gastroparesis, setting the admissibility standard for thousands of claims.
- A parallel MDL involving NAION vision-loss allegations is advancing through separate coordinated federal discovery, creating additional legal exposure for both drugmakers.
- The upcoming evidentiary rulings will decide whether thousands of consolidated patient lawsuits can proceed to jury trials or face widespread pre-trial dismissal.
Mass Tort
Mass Tort
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
